Bristol-Myers Squibb was developing BMS 903452, a GPR119 agonist, for the treatment of patients with type 2 diabetes mellitus. G-protein-coupled receptor 119 (GPR119) is expressed predominantly in pancreatic β-cells and in enteroendocrine cells in the gastrointestinal tract. GPR119 agonists have been shown to stimulate glucose-dependent insulin release by direct action in the pancreas and to promote the secretion of the incretin GLP-1 by action in the gastrointestinal tract. BMS 903452 participated in phase I clinical trials in healthy subjects and in patients with type 2 diabetes mellitus to evaluate the safety, tolerability, and effect on blood glucose control. However, further information is not available.